Lyra Therapeutics, Inc. (LYRA)

Lyra Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-93.44	-62.68	-55.28	-43.51	-22.13
Depreciation & Amortization	0.47	0.28	1.07	1	0.1
Other Amortization	0.14	-	-	-	-
Loss (Gain) From Sale of Assets	-	-	-	-	-0.05
Asset Writedown & Restructuring Costs	24.72	1.59	1.32	-	-
Loss (Gain) From Sale of Investments	-2.28	-3.5	-0.49	-	-
Stock-Based Compensation	6.72	5.89	5.45	2.77	1.81
Change in Accounts Payable	-1.89	0.45	-2.41	2.35	0.35
Change in Unearned Revenue	-1.53	-1.56	3.64	11.72	-
Change in Other Net Operating Assets	-2.93	-3.78	3.33	-0.14	-1.22
Operating Cash Flow	-70.01	-63.3	-43.39	-25.82	-21.14
Capital Expenditures	-2.34	-1.05	-0.16	-3.39	-1.78
Investment in Securities	82.64	-11.54	-64.84	-	-
Investing Cash Flow	80.31	-12.58	-65.01	-3.39	-1.78
Issuance of Common Stock	8.82	69.35	100.5	0.6	59.9
Other Financing Activities	-0.29	-3.65	-4.25	-0.25	-2.59
Financing Cash Flow	8.53	65.69	96.26	0.36	87.7
Net Cash Flow	18.83	-10.2	-12.13	-28.85	64.79
Free Cash Flow	-72.35	-64.35	-43.55	-29.21	-22.92
Free Cash Flow Margin	-4716.36%	-4130.36%	-3195.08%	-10247.37%	-
Free Cash Flow Per Share	-1.11	-1.29	-1.44	-2.25	-2.67
Levered Free Cash Flow	-39	-33.73	-33.03	-14.45	-15.17
Unlevered Free Cash Flow	-39.14	-33.73	-33.03	-14.45	-15.17
Change in Net Working Capital	6.03	-2.11	5.02	-12.43	1.42

Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q